$CNXX
CONX Corp.

2021 Form 10-K Financial Statement

#000110465922034061 Filed on March 16, 2022

View on sec.gov

Income Statement

Concept 2021 2020 Q4 2020 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $555.5K $150.0K $8.530K
YoY Change 247.18%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $555.5K $150.0K $8.530K
YoY Change 247.18%
Operating Profit -$555.5K -$8.525K
YoY Change
Interest Expense $19.93M $4.160M
YoY Change 379.09%
% of Operating Profit
Other Income/Expense, Net $19.93M -$1.880M
YoY Change -1160.11%
Pretax Income $19.37M $2.130M -$8.525K
YoY Change 813.89%
Income Tax $18.45K $0.00
% Of Pretax Income 0.1% 0.0%
Net Earnings $19.36M $2.130M -$8.525K
YoY Change 813.02%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $206.4K $24.98K -$88.33
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2021 2020 Q4 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $750.4K $1.200M $200.0K
YoY Change -37.47%
Cash & Equivalents $1.212M $220.0K
Short-Term Investments
Other Short-Term Assets $70.00K $0.00
YoY Change
Inventory
Prepaid Expenses $22.33K
Receivables
Other Receivables
Total Short-Term Assets $823.9K $1.238M $220.0K
YoY Change -31.34%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $750.1M
YoY Change
Other Assets $750.0M $400.0K
YoY Change
Total Long-Term Assets $750.1M $750.0M $358.0K
YoY Change 0.01%
TOTAL ASSETS
Total Short-Term Assets $823.9K $1.238M $220.0K
Total Long-Term Assets $750.1M $750.0M $358.0K
Total Assets $750.9M $751.2M $578.0K
YoY Change -0.04%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $0.00 $112.5K
YoY Change -100.0%
Accrued Expenses $286.0K $25.00K $188.5K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $400.0K
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $298.8K $138.6K $561.5K
YoY Change 198.76%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $52.40M $300.0K
YoY Change 17365.56%
Total Long-Term Liabilities $52.40M $300.0K $0.00
YoY Change 17365.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $298.8K $138.6K $561.5K
Total Long-Term Liabilities $52.40M $300.0K $0.00
Total Liabilities $52.70M $72.39M $600.0K
YoY Change -27.22%
SHAREHOLDERS EQUITY
Retained Earnings -$71.15M -$8.525K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $698.2M -$71.15M $0.00
YoY Change
Total Liabilities & Shareholders Equity $750.9M $751.2M $578.0K
YoY Change -0.04%

Cashflow Statement

Concept 2021 2020 Q4 2020 Q3
OPERATING ACTIVITIES
Net Income $19.36M $2.130M -$8.525K
YoY Change 813.02%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$461.5K -$120.0K
YoY Change 284.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 -$750.0M
YoY Change -100.0%
Cash From Investing Activities $0.00 -$750.0M
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $25.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 751.1M 220.0K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -461.5K -120.0K
Cash From Investing Activities 0.000 -750.0M
Cash From Financing Activities 0.000 751.1M 220.0K
Net Change In Cash -461.5K 990.0K 220.0K
YoY Change -138.14%
FREE CASH FLOW
Cash From Operating Activities -$461.5K -$120.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001823000
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021 conxu Threshold Trading Days For Redeem Public Shares After Completion Of Initial Business Combination
ThresholdTradingDaysForRedeemPublicSharesAfterCompletionOfInitialBusinessCombination
P10D
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39677
CY2021 dei Entity Registrant Name
EntityRegistrantName
CONX CORP.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-2728630
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
5701 S
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Santa Fe Dr
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Littleton
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CO
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
80120
CY2021 dei City Area Code
CityAreaCode
303
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1122
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71149143
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-51791191
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-71147267
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
750904232
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
751243021
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
555487
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
162382
CY2021 dei Local Phone Number
LocalPhoneNumber
472-1542
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
false
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2021 dei Entity Shell Company
EntityShellCompany
true
CY2021Q2 dei Entity Public Float
EntityPublicFloat
739500000
CY2021 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2021 dei Auditor Location
AuditorLocation
New York, New York
CY2021 dei Auditor Firm
AuditorFirmId
100
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
750369
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1211837
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
70000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
22333
CY2021Q4 us-gaap Other Receivables
OtherReceivables
3508
CY2020Q4 us-gaap Other Receivables
OtherReceivables
3508
CY2021Q4 us-gaap Assets Current
AssetsCurrent
823877
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1237678
CY2021Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
750080355
CY2020Q4 us-gaap Assets Held In Trust Noncurrent
AssetsHeldInTrustNoncurrent
750005343
CY2021Q4 us-gaap Assets
Assets
750904232
CY2020Q4 us-gaap Assets
Assets
751243021
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
112500
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
286011
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
12746
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
298757
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
138622
CY2021Q4 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2020Q4 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2021Q4 conxu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
26250000
CY2020Q4 conxu Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
26250000
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
25871666
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
45726666
CY2021Q4 us-gaap Liabilities
Liabilities
52695423
CY2020Q4 us-gaap Liabilities
Liabilities
72390288
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51793069
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-555487
us-gaap Operating Income Loss
OperatingIncomeLoss
-162382
conxu Fair Value Of Private Placement Warrants In Excess Of Proceeds
FairValueOfPrivatePlacementWarrantsInExcessOfProceeds
2875266
conxu Offering Costs Associated With Derivative Warrant Liabilities
OfferingCostsAssociatedWithDerivativeWarrantLiabilities
1879881
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-19855000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7030803
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
75012
us-gaap Investment Income Interest
InvestmentIncomeInterest
5343
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19930012
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2280999
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
19374525
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
2118617
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18449
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1122
CY2021 us-gaap Net Income Loss
NetIncomeLoss
19356076
us-gaap Net Income Loss
NetIncomeLoss
2117495
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-71147267
CY2021 us-gaap Net Income Loss
NetIncomeLoss
19356076
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-51791191
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
0
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-73289763
us-gaap Net Income Loss
NetIncomeLoss
2117495
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-71147267
CY2021 us-gaap Profit Loss
ProfitLoss
19356076
us-gaap Profit Loss
ProfitLoss
2117495
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
75012
us-gaap Investment Income Interest
InvestmentIncomeInterest
5343
conxu Fair Value Of Private Placement Warrants In Excess Of Proceeds
FairValueOfPrivatePlacementWarrantsInExcessOfProceeds
2875266
conxu Offering Costs Associated With Derivative Warrant Liabilities
OfferingCostsAssociatedWithDerivativeWarrantLiabilities
1879881
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-19855000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-7030803
CY2021 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
47667
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
22333
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
3508
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-112500
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
48000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
261011
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
25000
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
11624
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
1122
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-461468
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-115223
conxu Payments For Investment Of Cash In Trust Account
PaymentsForInvestmentOfCashInTrustAccount
750000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-750000000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
25000
conxu Proceeds From Other Related Party Debt
ProceedsFromOtherRelatedPartyDebt
373000
conxu Repayments Of Other Related Party Debt
RepaymentsOfOtherRelatedPartyDebt
373000
us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
17000000
conxu Net Proceeds From Initial Public Offering
NetProceedsFromInitialPublicOffering
735000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
697940
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation coverage limit of $250,000. At December 31, 2021, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.003
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
751327060
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-461468
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1211837
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1211837
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
750369
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1211837
conxu Deferred Legal Fees Included In Offering Costs
DeferredLegalFeesIncludedInOfferingCosts
275000
conxu Deferred Underwriting Fees Included In Offering Costs
DeferredUnderwritingFeesIncludedInOfferingCosts
26250000
CY2021 conxu Reinvestment Of Interest Earned On Trust Account Investments
ReinvestmentOfInterestEarnedOnTrustAccountInvestments
75012
conxu Reinvestment Of Interest Earned On Trust Account Investments
ReinvestmentOfInterestEarnedOnTrustAccountInvestments
5343
CY2020Q4 conxu Investment Maturity Period Of Initial Public Offering Proceeds Minimum
InvestmentMaturityPeriodOfInitialPublicOfferingProceedsMinimum
P185D
CY2021Q4 conxu Business Combination Percent To Trust Account
BusinessCombinationPercentToTrustAccount
0.80
CY2021Q4 conxu Business Combination Post Transaction Company Minimum Ownership
BusinessCombinationPostTransactionCompanyMinimumOwnership
0.50
CY2021Q4 conxu Redemption Price Of Shares Sold In Initial Public Offering
RedemptionPriceOfSharesSoldInInitialPublicOffering
10.00
CY2021 conxu Minimum Net Tangible Assets Upon Consummation Of Business Combination
MinimumNetTangibleAssetsUponConsummationOfBusinessCombination
5000001
CY2021 conxu Obligation To Redeem Percentage Of Common Stock With Respect To Any Other Material Provision Relating To Stockholders Rights Or Pre Initial Business Combination Activity
ObligationToRedeemPercentageOfCommonStockWithRespectToAnyOtherMaterialProvisionRelatingToStockholdersRightsOrPreInitialBusinessCombinationActivity
1
CY2021Q4 conxu Redemption Price Of Shares Sold In Initial Public Offering
RedemptionPriceOfSharesSoldInInitialPublicOffering
10.00
CY2021 us-gaap Derivatives Methods Of Accounting Hedging Derivatives
DerivativesMethodsOfAccountingHedgingDerivatives
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="font-style:italic;font-weight:bold;">Derivative Financial Instruments </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC 815, “Derivatives and Hedging”. The Company’s derivative instruments are recorded at fair value as of the IPO (November 3, 2020) and re-valued at each reporting date, with changes in the fair value reported in the Statements of Operations. Derivative assets and liabilities are classified on the Balance Sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the Balance Sheet date. The Company has determined the Warrants are a derivative instrument. As the Warrants meet the definition of a derivative the Warrants are measured at fair value at issuance and at each reporting date in accordance with ASC 820, “Fair Value Measurements and Disclosures,” with changes in fair value recognized in the Statement of Operations in the period of change.</p>
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
3413
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
23108
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
124010
us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
34100
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18449
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1122
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2021 conxu Investment Maturity Period Of Initial Public Offering Proceeds Minimum
InvestmentMaturityPeriodOfInitialPublicOfferingProceedsMinimum
P185D
CY2021Q4 us-gaap Net Asset Value Per Share
NetAssetValuePerShare
1.00
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 18pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities during the reporting period. The determination of the fair value of the warrant liabilities is a significant accounting estimate included in these financial statements. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates.</p>
CY2021Q4 conxu Redemption Price Of Shares Sold In Initial Public Offering
RedemptionPriceOfSharesSoldInInitialPublicOffering
10.00
CY2021 conxu Redemption Of Percentage Of Common Stock Included In Units Sold In Offering
RedemptionOfPercentageOfCommonStockIncludedInUnitsSoldInOffering
0.15
CY2021Q4 conxu Deferred Tax Assets Startup And Organizational Costs
DeferredTaxAssetsStartupAndOrganizationalCosts
87767
CY2020Q4 conxu Deferred Tax Assets Startup And Organizational Costs
DeferredTaxAssetsStartupAndOrganizationalCosts
28850
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
70343
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
5250
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
158110
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
34100
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
158110
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
34100
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
15035
us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
1122
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
100903
us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
34100
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 conxu Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Warrant Liabilities Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeWarrantLiabilitiesPercent
0.215
conxu Effective Income Tax Rate Reconciliation Change In Fair Value Of Derivative Warrant Liabilities Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfDerivativeWarrantLiabilitiesPercent
0.207
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.006
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 conxu Founder Shares Hold Period From Business Combination
FounderSharesHoldPeriodFromBusinessCombination
P180D
CY2021 conxu Threshold Period For Not To Transfer Assign Or Sell Any Shares Or Warrants After Completion Of Initial Business Combination
ThresholdPeriodForNotToTransferAssignOrSellAnySharesOrWarrantsAfterCompletionOfInitialBusinessCombination
P30D
CY2021Q4 conxu Cash Underwriting Discount Per Unit
CashUnderwritingDiscountPerUnit
0.20
CY2021 conxu Payment Of Underwriter Discount
PaymentOfUnderwriterDiscount
15000000
CY2021Q4 conxu Deferred Fee Per Unit
DeferredFeePerUnit
0.35
CY2021Q4 conxu Deferred Legal Fees
DeferredLegalFees
275000
CY2021 conxu Percent Of Difference Between Total Return And Price Threshold Multiplied By Sum Of Any Stock Splits Stock Capitalizations Stock Combinations Stock Dividends Reorganizations Recapitalizations
PercentOfDifferenceBetweenTotalReturnAndPriceThresholdMultipliedBySumOfAnyStockSplitsStockCapitalizationsStockCombinationsStockDividendsReorganizationsRecapitalizations
0.20
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
25871666
CY2020Q4 us-gaap Shares Subject To Mandatory Redemption Settlement Terms Fair Value Of Shares
SharesSubjectToMandatoryRedemptionSettlementTermsFairValueOfShares
45726666
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
52757667
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-4155537
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
-56913204
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
45726666
CY2021 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
19855000
CY2021Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
25871666

Files In Submission

Name View Source Status
0001104659-22-034061-index-headers.html Edgar Link pending
0001104659-22-034061-index.html Edgar Link pending
0001104659-22-034061.txt Edgar Link pending
0001104659-22-034061-xbrl.zip Edgar Link pending
conxu-20211231.xsd Edgar Link pending
conxu-20211231x10k.htm Edgar Link pending
conxu-20211231x10k_htm.xml Edgar Link completed
conxu-20211231xex31d1.htm Edgar Link pending
conxu-20211231xex32d1.htm Edgar Link pending
conxu-20211231_cal.xml Edgar Link unprocessable
conxu-20211231_def.xml Edgar Link unprocessable
conxu-20211231_lab.xml Edgar Link unprocessable
conxu-20211231_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending